"Amgen’s gMG therapy cuts disease symptoms at one-year mark" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...

giving people more choices to manage their symptoms and improve their quality of life.” While current treatments exist for gMG, many patients experience incomplete symptom relief or challenging ...

The recently completed ME&MGopen study aimed to evaluate a smartphone-based tool designed to track gMG symptoms using digital biomarkers and patient-reported outcomes. It included 225 patients ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

MuSK antibody positive adults and pediatric gMG patients aged 12 and older. FDA Approves New Treatment for Generalized ...